Risk factors for haemorrhage in thrombocytopenic haematology patients: a pilot clinical investigation

HS Blood & Transplant (NHSBT) (UK)0 个研究点目标入组 50 人开始时间: 2012年11月20日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Adult patients with a haematological malignancy requiring myeloablative chemotherapy or a stem cell transplant
•2. Aged 16 years or over
•3. Confirmed diagnosis of a haematological malignancy
•4. Received, are receiving or are going to receive myelosuppressive chemotherapy on this hospital admission with or without haematopoietic stem cell support (this includes patients undergoing haemopoietic stem cell transplantation -autograft or allograft)
•5. Thrombocytopenic or expected to become thrombocytopenic with a platelet count of less than 50 x 10E9/L for at least 5 days
•6. Will be treated as an in-patient during their period of thrombocytopenia
•7. Able to comply with monitoring

•1. Inherited clotting disorder (e.g. haemophilia)
•2. Patients need to remain on regular aspirin (or related drugs), or will require regular doses of anticoagulants (heparin), during the whole period of thrombocytopenia
•3. Previously recruited to this study at any stage of their treatment
•4. Diagnosed with or with a history of immune thrombocytopenia

发起方

HS Blood & Transplant (NHSBT) (UK)